Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	120059
Country	United States

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Cohort Study
Article Title	Clinical outcomes of upadacitinib dose escalation in inflammatory bowel disease: A single-center retrospective cohort study
Manuscript Source	Unsolicited Manuscript
All Author List	Abigail Layton Ellington, Danielle Rambuss, Sarah Barbina and Maithili Chitnavis
Funding Agency and Grant Number
Corresponding Author	Abigail Layton Ellington, MD, Internal Medicine, Atrium Health Wake Forest Baptist, 1 Medical Center Blvd, Winston-Salem, NC 27157, United States. abigail.ellington@advocatehealth.org
Key Words	Upadacitinib; Janus kinase 1 inhibitor; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Dose intensification; Secondary loss of response; Real-world evidence; Treatment durability; Corticosteroid reduction
Core Tip	Real-world data guiding dose re-escalation of upadacitinib in inflammatory bowel disease (IBD) are limited. In this single-center cohort, off-label intensification in patients with secondary loss of response was associated with significant symptomatic improvement and reduced corticosteroid exposure, with favorable trends in objective measures. Most patients remained on the escalated dose at follow-up. No new laboratory safety signals were observed. These findings suggest dose intensification may represent a pragmatic management strategy in selected patients with IBD.
Citation	Ellington AL, Rambuss D, Barbina S, Chitnavis M. Clinical outcomes of upadacitinib dose escalation in inflammatory bowel disease: A single-center retrospective cohort study. World J Gastrointest Pharmacol Ther 2026; In press

Received	2026-02-14 03:02
Peer-Review Started	2026-02-14 03:03
First Decision by Editorial Office Director	2026-02-26 07:31
Return for Revision	2026-02-26 07:31
Revised	2026-03-10 01:15
Publication Fee Transferred	2026-03-26 19:00
Second Decision by Editor	2026-04-15 02:37
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-04-15 08:23
Articles in Press	2026-04-15 08:23
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2150-5349 (online)
Open Access	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com